How does tigecycline affect liver tests (ALT, AST, bilirubin)?
Tigecycline can cause liver-related lab abnormalities, but clinically significant liver injury is less common than mild, self-limited increases in liver enzymes. When it happens, patterns range from mild transaminase elevations to cholestatic or mixed liver test abnormalities, and in rare cases severe drug-induced liver injury has been reported.
What do clinicians look for: ALT/AST vs bilirubin and cholestasis?
Clinicians typically monitor:
- Rising ALT and AST (hepatocellular pattern).
- Changes in bilirubin, especially if accompanied by alkaline phosphatase or other cholestatic features (cholestatic or mixed pattern).
- Trends over time after starting tigecycline, because liver test elevations that worsen or do not improve may signal clinically meaningful injury rather than a transient lab change.
Is tigecycline associated with “overall liver function” worsening or just lab changes?
“Overall liver function” depends on whether enzyme elevations remain limited to lab abnormalities or progress to impaired synthetic function (for example, rising bilirubin plus worsening coagulation markers or clinical jaundice). The main practical impact described for tigecycline is liver enzyme elevations; true impairment of liver function is reported less often.
Who is at higher risk for liver problems with tigecycline?
Risk is higher in people who already have:
- Baseline liver disease or impaired hepatic reserve.
- Critical illness or sepsis, which can independently affect liver enzymes and bilirubin.
- Concomitant hepatotoxic medications.
- Longer exposure durations, since drug-related liver test changes can evolve while treatment continues.
What happens if liver tests rise during treatment?
Common clinical approaches include:
- Recheck liver enzymes and bilirubin to confirm whether the abnormality is improving or progressing.
- Review other causes (progressing infection, biliary obstruction, viral hepatitis, alcohol-related injury, and other medications).
- Consider dose adjustment or stopping tigecycline if liver test abnormalities meet criteria for clinically significant drug-induced liver injury (particularly if bilirubin rises, liver tests continue to worsen, or symptoms like jaundice occur).
What monitoring is typically recommended?
In practice, clinicians often monitor liver function tests (ALT/AST and bilirubin) during therapy, especially for patients with:
- Pre-existing liver disease.
- Prolonged treatment courses.
- Marked baseline abnormalities.
- New symptoms such as jaundice, dark urine, right upper quadrant pain, unexplained fatigue, or severe nausea/vomiting.
How does tigecycline compare with other antibiotics in terms of liver risk?
Tigecycline is generally not the highest-risk antibiotic for serious liver injury compared with some other drug classes, but it still can produce meaningful liver enzyme abnormalities. The key difference in real-world impact often comes down to the rate and severity of lab trends and whether patients have overlapping risk factors like sepsis or polypharmacy.
Sources
I don’t have any tigecycline-specific liver-function impact data from the provided information, and I can’t reliably cite a source. If you share the relevant prescribing information excerpt (or a study/guideline link) you’re using, I can summarize exactly what it reports about liver enzymes, bilirubin, and clinically significant hepatic impairment and translate it into plain language.